Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Obeticholic Acid216 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00474 | 35068796 | J Clin Exp Hepatol | A Current Understanding of Bile Acids in Chronic Liver Disease. | 2021 | Details |
| A00500 | 35060815 | Expert Opin Investig Drugs | Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. | 2022 | Details |
| A00700 | 34998040 | Eur J Med Chem | Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis. | 2021 | Details |
| A00831 | 34954593 | Eur J Med Chem | Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. | 2021 | Details |
| A01068 | 34881283 | Front Nutr | Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity. | 2021 | Details |
| A01124 | 34862975 | FASEB J | Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. | 2022 | Details |
| A01311 | 34793868 | J Hepatol | Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. | 2021 | Details |
| A01634 | 34675338 | Sci Rep | Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis. | 2021 | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | 2021 | Details |
| A02030 | 34526653 | Commun Biol | Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. | 2021 | Details |
| A02287 | 34435378 | Aliment Pharmacol Ther | Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. | 2021 | Details |
| A02330 | 34416040 | Aliment Pharmacol Ther | Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. | 2021 | Details |
| A02557 | 34328687 | Liver Int | Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. | 2021 | Details |
| A02909 | 34200685 | Metabolites | Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid. | 2021 | Details |
| A03126 | 34119888 | Biomaterials | A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids. | 2021 | Details |
| A03317 | 34047448 | Mol Nutr Food Res | Soyasaponin A2 Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline-Deficient (MCD) Diet-induced Nonalcoholic Steatohepatitis (NASH) Mice. | 2021 | Details |
| A03482 | 33987427 | Ann Transl Med | Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. | 2021 | Details |
| A03484 | 33987424 | Ann Transl Med | Non-alcoholic fatty liver diseases: current challenges and future directions. | 2021 | Details |
| A03493 | 33984334 | Metabolism | A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage. | 2021 | Details |
| A03845 | 33849361 | Expert Opin Drug Discov | The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. | 2021 | Details |
| A04029 | 33784797 | Phytother Res | Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice. | 2021 | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | 2021 | Details |
| A04188 | 33722778 | Clin Res Hepatol Gastroenterol | Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis. | 2021 | Details |
| A04213 | 33711479 | Clin Gastroenterol Hepatol | Treatment Candidacy for Pharmacologic Therapies for NASH. | 2021 | Details |
| A04289 | 33675775 | Biochem Pharmacol | Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model. | 2021 | Details |
| A04466 | 33604254 | J Clin Transl Hepatol | Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. | 2020 | Details |
| A04700 | 33535836 | Expert Rev Clin Pharmacol | An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy. | 2021 | Details |
| A04743 | 33517537 | Tissue Eng Regen Med | Functional Analysis of Induced Human Ballooned Hepatocytes in a Cell Sheet-Based Three Dimensional Model. | 2021 | Details |
| A04749 | 33515800 | Ann Hepatol | Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. | 2021 | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | 2021 | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | 2021 | Details |
| A05237 | 33328206 | Diabetes | Defective FXR-SHP Regulation in Obesity Aberrantly Increases miR-802 Expression, Promoting Insulin Resistance and Fatty Liver. | 2020 | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | 2021 | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | 2020 | Details |
| A05930 | 33072533 | Adv Pharm Bull | The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. | 2020 | Details |
| A05966 | 33059584 | BMC Gastroenterol | Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF). | 2020 | Details |
| A06142 | 32991173 | J Med Chem | Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06430 | 32883049 | Cells | A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology. | 2020 | Details |
| A06522 | 32841505 | Liver Int | Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. | 2020 | Details |
| A06543 | 32832402 | J Clin Transl Hepatol | NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. | 2020 | Details |
| A06594 | 32814993 | Curr Gastroenterol Rep | Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06808 | 32738331 | Toxicol Appl Pharmacol | A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. | 2020 | Details |
| A06958 | 32686578 | Expert Opin Emerg Drugs | Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. | 2020 | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | 2020 | Details |
| A07203 | 32583961 | Clin Transl Sci | Evolving Role for Pharmacotherapy in NAFLD/NASH. | 2020 | Details |
| A07297 | 32552182 | Expert Opin Investig Drugs | Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). | 2020 | Details |
| A07313 | 32543284 | Expert Opin Pharmacother | Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. | 2020 | Details |
| A07480 | 32478287 | Nat Metab | Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. | 2020 | Details |
| A07589 | 32433419 | Eur J Gastroenterol Hepatol | Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. | 2021 | Details |
| A08004 | 32282030 | Br Med Bull | Obeticholic acid-a new therapy in PBC and NASH. | 2020 | Details |
| A08115 | 32241197 | Expert Rev Gastroenterol Hepatol | Obeticholic acid for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08128 | 32237916 | Expert Opin Pharmacother | Current and new pharmacotherapy options for non-alcoholic steatohepatitis. | 2020 | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08581 | 32052857 | Hepatology | New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. | 2020 | Details |
| A08711 | 32015483 | Sci Rep | Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. | 2020 | Details |
| A08782 | 31986416 | Biomed Pharmacother | Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis. | 2020 | Details |
| A08854 | 31965579 | Hepatology | Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. | 2020 | Details |
| A08915 | 31940200 | J Med Chem | Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08931 | 31932588 | Nat Commun | SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. | 2020 | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | 2020 | Details |
| A08999 | 31909357 | Hepatol Commun | A Microphysiological System for Studying Nonalcoholic Steatohepatitis. | 2019 | Details |
| A09076 | 31883408 | Liver Int | Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease. | 2020 | Details |
| A09261 | 31813633 | Lancet | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. | 2019 | Details |
| A09415 | 31757735 | Presse Med | [Pharmacological treatment of NASH]. | 2019 | Details |
| A09720 | 31634532 | J Hepatol | Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. | 2019 | Details |
| A09983 | 31536725 | Eur J Pharmacol | Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. | 2019 | Details |
| A10041 | 31516268 | J Clin Exp Hepatol | Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. | 2019 | Details |
| A10083 | 31495973 | Hepatol Res | Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. | 2019 | Details |
| A10233 | 31419514 | J Hepatol | Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. | 2019 | Details |
| A10276 | 31402538 | Liver Int | CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. | 2019 | Details |
| A10465 | 31325638 | Biochim Biophys Acta Mol Cell Biol Lipids | Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. | 2019 | Details |
| A10510 | 31308634 | Drug Des Devel Ther | The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. | 2019 | Details |
| A10633 | 31260793 | Contemp Clin Trials | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. | 2019 | Details |
| A10776 | 31197565 | Handb Exp Pharmacol | Nonsteroidal FXR Ligands: Current Status and Clinical Applications. | 2019 | Details |
| A11226 | 30986904 | Int J Mol Sci | Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. | 2019 | Details |
| A11463 | 30885145 | BMC Gastroenterol | The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. | 2019 | Details |
| A11919 | 30682184 | PLoS One | Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. | 2019 | Details |
| A12244 | 30549292 | Hepatology | Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. | 2019 | Details |
| A12332 | 30511198 | Dig Dis Sci | Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. | 2018 | Details |
| A12660 | 30341231 | Postgrad Med J | Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | 2018 | Details |
| A12729 | 30314377 | Pharmaceuticals (Basel) | Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A12835 | 30261763 | Expert Rev Gastroenterol Hepatol | An update on the recent advances in antifibrotic therapy. | 2018 | Details |
| A12856 | 30254132 | Dis Model Mech | A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. | 2018 | Details |
| A12859 | 30253043 | Liver Int | Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. | 2019 | Details |
| A12927 | 30222962 | Gastroenterology | Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. | 2018 | Details |
| A13228 | 30074500 | Curr Opin Endocrinol Diabetes Obes | Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. | 2018 | Details |
| A13453 | 29964161 | Pharmacol Res | Human-based systems: Mechanistic NASH modelling just around the corner? | 2018 | Details |
| A13470 | 29956213 | Adv Exp Med Biol | Current Prevention and Treatment Options for NAFLD. | 2018 | Details |
| A13700 | 29802399 | Sci Rep | Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. | 2018 | Details |
| A13821 | 29743187 | Mol Pharmacol | Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation. | 2018 | Details |
| A13909 | 29697548 | J Pediatr Gastroenterol Nutr | Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment. | 2018 | Details |
| A14000 | 29649907 | Expert Opin Ther Pat | Farnesoid X receptor modulators 2014-present: a patent review. | 2018 | Details |
| A14424 | 29413959 | Redox Biol | Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. | 2018 | Details |
| A14512 | 29375205 | World J Gastroenterol | INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. | 2018 | Details |
| A14513 | 29375204 | World J Gastroenterol | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. | 2018 | Details |
| A14595 | 29333665 | Aliment Pharmacol Ther | Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. | 2018 | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | 2017 | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017 | Details |
| A14960 | 29155143 | Eur J Pharmacol | Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model. | 2017 | Details |
| A15013 | 29128056 | Clin Liver Dis | Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | 2017 | Details |